113 related articles for article (PubMed ID: 2112656)
1. [Interferon alpha and gamma in the treatment of renal cell carcinoma].
Kawai K; Sato K; Nishijima Y; Sasaki A; Yamashita J; Ishikawa H; Koiso K
Nihon Jinzo Gakkai Shi; 1990 Feb; 32(2):231-6. PubMed ID: 2112656
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of renal cell carcinoma. 3. Interferon therapy].
Kobayashi M; Imai K; Kiren H; Nakai K; Saruki K; Umeyama T; Ito Y; Yamanaka H; Makino T; Machida M
Hinyokika Kiyo; 1987 Apr; 33(4):508-14. PubMed ID: 3618421
[TBL] [Abstract][Full Text] [Related]
3. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
5. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.
Gleave ME; Elhilali M; Fradet Y; Davis I; Venner P; Saad F; Klotz LH; Moore MJ; Paton V; Bajamonde A
N Engl J Med; 1998 Apr; 338(18):1265-71. PubMed ID: 9562580
[TBL] [Abstract][Full Text] [Related]
6. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
[TBL] [Abstract][Full Text] [Related]
8. [Effect of recombinant alpha-interferon on advanced renal cell carcinoma].
Isaka S; Okano T; Akimoto S; Shimazaki J; Murakami S; Igarashi T; Kitamura Y; Yamaguchi K; Kataumi S; Ohtsuka K
Hinyokika Kiyo; 1985 Dec; 31(12):2209-14. PubMed ID: 3832921
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
10. [The treatment of renal cell carcinoma with recombinant human leukocyte interferon].
Kawamura J; Yamauchi T; Hashimura T; Yoshida O; Kohnami T; Tomoyoshi T; Ogura K; Fukuyama T; Nakagawa K
Hinyokika Kiyo; 1985 Mar; 31(3):377-86. PubMed ID: 4025077
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and pharmacokinetics of continuous subcutaneous infusion of low-dose interferon-gamma: a pilot study.
Satake I; Tari K; Nakagomi K; Ozawa K
Jpn J Clin Oncol; 1993 Dec; 23(6):356-62. PubMed ID: 8283789
[TBL] [Abstract][Full Text] [Related]
12. [Successful cumulative treatment with pre/post-operative interferon-alpha, nephrectomy, and surgical resection of metastasis in advanced renal cell carcinoma : a case report].
Hisamatsu H; Yamashita S
Hinyokika Kiyo; 2010 Mar; 56(3):155-8. PubMed ID: 20372043
[TBL] [Abstract][Full Text] [Related]
13. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
Itano NB; Blute ML; Spotts B; Zincke H
J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
[TBL] [Abstract][Full Text] [Related]
14. [Combination therapy of renal cell carcinoma with interferon-alpha and UFT (or FT-207)].
Kobayashi M; Imai K; Yamanaka H; Takahashi H; Mashimo T; Shimizu N; Koya J; Yajima H; Kawashima K; Kitaura K
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1437-46. PubMed ID: 2509605
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.
Vugrin D; Hood L; Taylor W; Laszlo J
Cancer Treat Rep; 1985; 69(7-8):817-20. PubMed ID: 4016792
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
17. [Phase II study of recombinant human interferon gamma (S-6810) in renal cell carcinoma. Urological Cooperative Study Group of Recombinant Human Interferon Gamma (S-6810)].
Machida T; Koiso K; Takaku F; Ogawa M
Gan To Kagaku Ryoho; 1987 Feb; 14(2):440-5. PubMed ID: 3101607
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effects and immunological changes in interferon therapy for advanced renal cell carcinoma].
Kudo T; Souma H; Kudo S; Kogawa T; Suzuki T
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):40-6. PubMed ID: 2109026
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
[TBL] [Abstract][Full Text] [Related]
20. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
Kuzmits R; Scheithauer W; Ludwig H; Flener R
Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
